Methylphenidate in mania project (MEMAP): Study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate

Michael Kluge, Ulrich Hegerl, Christian Sander, Jens Dietzel, Roland Mergl, I. Bitter, Koen Demyttenaere, Ricardo Gusmão, Ana Gonzalez-Pinto, Victor Perez-Sola, Eduard Vieta, Georg Juckel, Ulrich S. Zimmermann, Michael Bauer, Pascal Sienaert, Sónia Quintão, Marc Andreas Edel, Csilla Bolyos, Jose Luis Ayuso-Mateos, Pilar López-García

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Treatment of patients with acute mania remains a considerable medical challenge since onset of action of antimanic medication is delayed for several days. Psychostimulants could have an earlier onset of action. This assumption is based on the 'vigilance regulation model of mania' which postulates that vigilance is unstable in manic patients. Accordingly, vigilance-stabilising psychostimulants could be more useful than conventional treatment in acute mania. We present here the study protocol of a trial intended to study the efficacy and safety of methylphenidate in the initial treatment of acute mania.Methods/design: A multi-centre, randomised, double-blind, placebo-controlled clinical trial will be conducted in 88 bipolar inpatients with acute mania. Male and female patients older than 18 years will be randomised to treatment with either methylphenidate (20 to 40 mg/day) or placebo for 2.5 days, given once or twice daily. The main outcome measure is the reduction in the Young Mania Rating Scale (YMRS) after 2.5 days of treatment. Other outcome measures include the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) the Clinical Global Impression-Bipolar Scale (CGI-BP), the Screen for Cognitive Impairment in Psychiatry (SCIP), actigraphy and the EEG-'Vigilance Algorithm Leipzig' (VIGALL).Discussion: A positive study outcome of the proposed study could substantially impact our understanding of the etiopathogenesis of mania and open new treatment perspectives.Trial registration: ClinicalTrials.gov: NCT 01541605.

Original languageEnglish
Article number71
JournalBMC Psychiatry
Volume13
DOIs
Publication statusPublished - Feb 27 2013

Fingerprint

Methylphenidate
Bipolar Disorder
Placebos
Outcome Assessment (Health Care)
Therapeutics
Antimanic Agents
Actigraphy
Controlled Clinical Trials
Clinical Protocols
Psychiatry
Inpatients
Electroencephalography
Safety

Keywords

  • Bipolar disorder
  • EEG
  • Mania
  • Methylphenidate
  • Psychostimulants
  • Vigilance

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Methylphenidate in mania project (MEMAP) : Study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate. / Kluge, Michael; Hegerl, Ulrich; Sander, Christian; Dietzel, Jens; Mergl, Roland; Bitter, I.; Demyttenaere, Koen; Gusmão, Ricardo; Gonzalez-Pinto, Ana; Perez-Sola, Victor; Vieta, Eduard; Juckel, Georg; Zimmermann, Ulrich S.; Bauer, Michael; Sienaert, Pascal; Quintão, Sónia; Edel, Marc Andreas; Bolyos, Csilla; Ayuso-Mateos, Jose Luis; López-García, Pilar.

In: BMC Psychiatry, Vol. 13, 71, 27.02.2013.

Research output: Contribution to journalArticle

Kluge, M, Hegerl, U, Sander, C, Dietzel, J, Mergl, R, Bitter, I, Demyttenaere, K, Gusmão, R, Gonzalez-Pinto, A, Perez-Sola, V, Vieta, E, Juckel, G, Zimmermann, US, Bauer, M, Sienaert, P, Quintão, S, Edel, MA, Bolyos, C, Ayuso-Mateos, JL & López-García, P 2013, 'Methylphenidate in mania project (MEMAP): Study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate', BMC Psychiatry, vol. 13, 71. https://doi.org/10.1186/1471-244X-13-71
Kluge, Michael ; Hegerl, Ulrich ; Sander, Christian ; Dietzel, Jens ; Mergl, Roland ; Bitter, I. ; Demyttenaere, Koen ; Gusmão, Ricardo ; Gonzalez-Pinto, Ana ; Perez-Sola, Victor ; Vieta, Eduard ; Juckel, Georg ; Zimmermann, Ulrich S. ; Bauer, Michael ; Sienaert, Pascal ; Quintão, Sónia ; Edel, Marc Andreas ; Bolyos, Csilla ; Ayuso-Mateos, Jose Luis ; López-García, Pilar. / Methylphenidate in mania project (MEMAP) : Study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate. In: BMC Psychiatry. 2013 ; Vol. 13.
@article{4e1ff403958946308056fb42cfd207f0,
title = "Methylphenidate in mania project (MEMAP): Study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate",
abstract = "Background: Treatment of patients with acute mania remains a considerable medical challenge since onset of action of antimanic medication is delayed for several days. Psychostimulants could have an earlier onset of action. This assumption is based on the 'vigilance regulation model of mania' which postulates that vigilance is unstable in manic patients. Accordingly, vigilance-stabilising psychostimulants could be more useful than conventional treatment in acute mania. We present here the study protocol of a trial intended to study the efficacy and safety of methylphenidate in the initial treatment of acute mania.Methods/design: A multi-centre, randomised, double-blind, placebo-controlled clinical trial will be conducted in 88 bipolar inpatients with acute mania. Male and female patients older than 18 years will be randomised to treatment with either methylphenidate (20 to 40 mg/day) or placebo for 2.5 days, given once or twice daily. The main outcome measure is the reduction in the Young Mania Rating Scale (YMRS) after 2.5 days of treatment. Other outcome measures include the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) the Clinical Global Impression-Bipolar Scale (CGI-BP), the Screen for Cognitive Impairment in Psychiatry (SCIP), actigraphy and the EEG-'Vigilance Algorithm Leipzig' (VIGALL).Discussion: A positive study outcome of the proposed study could substantially impact our understanding of the etiopathogenesis of mania and open new treatment perspectives.Trial registration: ClinicalTrials.gov: NCT 01541605.",
keywords = "Bipolar disorder, EEG, Mania, Methylphenidate, Psychostimulants, Vigilance",
author = "Michael Kluge and Ulrich Hegerl and Christian Sander and Jens Dietzel and Roland Mergl and I. Bitter and Koen Demyttenaere and Ricardo Gusm{\~a}o and Ana Gonzalez-Pinto and Victor Perez-Sola and Eduard Vieta and Georg Juckel and Zimmermann, {Ulrich S.} and Michael Bauer and Pascal Sienaert and S{\'o}nia Quint{\~a}o and Edel, {Marc Andreas} and Csilla Bolyos and Ayuso-Mateos, {Jose Luis} and Pilar L{\'o}pez-Garc{\'i}a",
year = "2013",
month = "2",
day = "27",
doi = "10.1186/1471-244X-13-71",
language = "English",
volume = "13",
journal = "BMC Psychiatry",
issn = "1471-244X",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Methylphenidate in mania project (MEMAP)

T2 - Study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate

AU - Kluge, Michael

AU - Hegerl, Ulrich

AU - Sander, Christian

AU - Dietzel, Jens

AU - Mergl, Roland

AU - Bitter, I.

AU - Demyttenaere, Koen

AU - Gusmão, Ricardo

AU - Gonzalez-Pinto, Ana

AU - Perez-Sola, Victor

AU - Vieta, Eduard

AU - Juckel, Georg

AU - Zimmermann, Ulrich S.

AU - Bauer, Michael

AU - Sienaert, Pascal

AU - Quintão, Sónia

AU - Edel, Marc Andreas

AU - Bolyos, Csilla

AU - Ayuso-Mateos, Jose Luis

AU - López-García, Pilar

PY - 2013/2/27

Y1 - 2013/2/27

N2 - Background: Treatment of patients with acute mania remains a considerable medical challenge since onset of action of antimanic medication is delayed for several days. Psychostimulants could have an earlier onset of action. This assumption is based on the 'vigilance regulation model of mania' which postulates that vigilance is unstable in manic patients. Accordingly, vigilance-stabilising psychostimulants could be more useful than conventional treatment in acute mania. We present here the study protocol of a trial intended to study the efficacy and safety of methylphenidate in the initial treatment of acute mania.Methods/design: A multi-centre, randomised, double-blind, placebo-controlled clinical trial will be conducted in 88 bipolar inpatients with acute mania. Male and female patients older than 18 years will be randomised to treatment with either methylphenidate (20 to 40 mg/day) or placebo for 2.5 days, given once or twice daily. The main outcome measure is the reduction in the Young Mania Rating Scale (YMRS) after 2.5 days of treatment. Other outcome measures include the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) the Clinical Global Impression-Bipolar Scale (CGI-BP), the Screen for Cognitive Impairment in Psychiatry (SCIP), actigraphy and the EEG-'Vigilance Algorithm Leipzig' (VIGALL).Discussion: A positive study outcome of the proposed study could substantially impact our understanding of the etiopathogenesis of mania and open new treatment perspectives.Trial registration: ClinicalTrials.gov: NCT 01541605.

AB - Background: Treatment of patients with acute mania remains a considerable medical challenge since onset of action of antimanic medication is delayed for several days. Psychostimulants could have an earlier onset of action. This assumption is based on the 'vigilance regulation model of mania' which postulates that vigilance is unstable in manic patients. Accordingly, vigilance-stabilising psychostimulants could be more useful than conventional treatment in acute mania. We present here the study protocol of a trial intended to study the efficacy and safety of methylphenidate in the initial treatment of acute mania.Methods/design: A multi-centre, randomised, double-blind, placebo-controlled clinical trial will be conducted in 88 bipolar inpatients with acute mania. Male and female patients older than 18 years will be randomised to treatment with either methylphenidate (20 to 40 mg/day) or placebo for 2.5 days, given once or twice daily. The main outcome measure is the reduction in the Young Mania Rating Scale (YMRS) after 2.5 days of treatment. Other outcome measures include the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) the Clinical Global Impression-Bipolar Scale (CGI-BP), the Screen for Cognitive Impairment in Psychiatry (SCIP), actigraphy and the EEG-'Vigilance Algorithm Leipzig' (VIGALL).Discussion: A positive study outcome of the proposed study could substantially impact our understanding of the etiopathogenesis of mania and open new treatment perspectives.Trial registration: ClinicalTrials.gov: NCT 01541605.

KW - Bipolar disorder

KW - EEG

KW - Mania

KW - Methylphenidate

KW - Psychostimulants

KW - Vigilance

UR - http://www.scopus.com/inward/record.url?scp=84874708766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874708766&partnerID=8YFLogxK

U2 - 10.1186/1471-244X-13-71

DO - 10.1186/1471-244X-13-71

M3 - Article

C2 - 23446109

AN - SCOPUS:84874708766

VL - 13

JO - BMC Psychiatry

JF - BMC Psychiatry

SN - 1471-244X

M1 - 71

ER -